肺癌基因突变分子靶向治疗

《肺癌基因突变分子靶向治疗》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、NCCN2018第2期第NSCL・H页载文如下：NCCNGuidelinesVersion2.2018Non-SmallCellLungCancerNSCL-HEMERGINGTARGETEDAGENTSFORPATIENTSWITHGENETICALTERATIONSGeneticAlteration(ie,Driverevent)AvailableTargetedAgentswithActivityAgainstDriverEventinLungCancerHigh-levelMETamplificationorMETexon14skippingmut

2、ationCrizotinib1'5RETrearrangementsCabozantinib'?Vandetanib8HER2mutationsAdo-trastuzumabemtansine?译为中文即：基因改变患者的靶向性药物基因改变（即驱动事件）肺癌驱动事件可用活性靶向剂高水平MET扩增或MET外显子14跳跃突变克卩坐替尼Crizotinib1'5RET重排卡博替尼Cabozantinib6,7凡徳他尼Vandetanib*HER2突变阿曲曲单抗Ado-trastuzumabemtansine?【角注原文】'OuSH,KwakEL,Siwak-Ta

3、ppC,etal.Activityofcrizotinib(PF02341066),adualmesenchymal-epithelialtransition(MET)andanaplasticlymphomakinase(ALK)inhibitor,inanon-smallcelllungcancerpatientwithdenovoMETamplification.JThoracOncol2011;6:942-946.2CamidgeRD,OuS-HI,ShapiroG,etal.Efficacyandsafetyofcrizotinibinpatie

4、ntswithadvancedc-MET-amplifiednon-smallcelllungcancer.JClinOncol2014;32(Suppl5):Abstract8001.'FramptonGM,AliSM,RosenzweigM,etal.ActivationofMETviadiverseexon14splicingalterationsoccursinmultipletumortypesandconfersclinicalsensitivitytoMETinhibitors.CancerDiscov2015;5:850-859.4Paik

5、PK,DrilonA,FanPD,etal.ResponsetoMETinhibitorsinpatientswithstageIVlungadenocarcinomasharboringMETmutationscausingexon14skipping.CancerDiscov2015;5:842-849.'AwadMM,OxnardGR,JackmanDM,etal.METexon14mutationsinnon-small-celllungcancerareassociatedwithadvaneedageandstage-dependentMETg

6、enomicamplificationandcMEToverexpresion.JClinOncol2016;34:721-730.6DrilonA,WangL，HasanovicA,etal.ResponsetocabozantinibinpatientswithRETfusionpositivelungadenocarcinomas.CancerDiscov2013;3:630-635.DrilonA,RekhtmanN,ArcilaM,etal.CabozantinibinpatientswithadvancedRET-rearrangednon-

7、small-celllungcancer:anopen-label,single-centre,phase2,single-armtrial.LancetOncol2016;17:1653-1660.oLeeSH,LeeJK,AhnMJ,etal.Vandetanibinpretreatedpatientswithadvancednon-smallcelllungcancer-harboringRETrearrangement:aphaseIIclinicaltrial.AnnOncol2017;28:292-297.9LiBT,ShenR,Buonoco

8、reD,etal.Ado-trastuzumabemtansine